To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Solid Tumours
Related studies linked through entity extraction aliases.
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
- Status
- COMPLETED
- Phase
- N/A
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
- Status
- TERMINATED
- Phase
- PHASE1
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
- Status
- COMPLETED
- Phase
- PHASE2
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
- Status
- COMPLETED
- Phase
- PHASE1
D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
- Status
- COMPLETED
- Phase
- N/A
Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1